Quick answers
- What is Levoxyl?
- Levoxyl is a brand name of Levothyroxine, a prescription medicine. The FDA NDC Directory lists 11 Levoxyl products in 11 strengths and forms.
- Who makes Levoxyl?
- King Pharms holds the FDA application for Levoxyl (NDA021301, approved May 25, 2001).
- Is there a generic or store brand of Levoxyl?
- Yes. The FDA NDC Directory lists 329 other products with the same active ingredients, strength and form as a Levoxyl product, 243 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Levoxyl?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 11 Levoxyl strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Levoxyl been recalled?
- FDA enforcement reports list 26 recalls of Levoxyl products; the newest started July 29, 2025. A recall usually concerns specific lots, not every product.
What Levoxyl is
Each Levoxyl product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Levothyroxine · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| levothyroxine sodium 100 ug tablet (oral) | Levoxyl | 37 products, 22 companies | DailyMed |
| levothyroxine sodium 112 ug tablet (oral) | Levoxyl | 28 products, 16 companies | DailyMed |
| levothyroxine sodium 125 ug tablet (oral) | Levoxyl | 31 products, 18 companies | DailyMed |
| levothyroxine sodium 137 ug tablet (oral) | Levoxyl | 28 products, 19 companies | DailyMed |
| levothyroxine sodium 150 ug tablet (oral) | Levoxyl | 26 products, 17 companies | DailyMed |
| levothyroxine sodium 175 ug tablet (oral) | Levoxyl | 25 products, 15 companies | DailyMed |
| levothyroxine sodium 200 ug tablet (oral) | Levoxyl | 25 products, 16 companies | DailyMed |
| levothyroxine sodium 25 ug tablet (oral) | Levoxyl | 27 products, 17 companies | DailyMed |
| levothyroxine sodium 50 ug tablet (oral) | Levoxyl | 36 products, 19 companies | DailyMed |
| levothyroxine sodium 75 ug tablet (oral) | Levoxyl | 34 products, 21 companies | DailyMed |
| levothyroxine sodium 88 ug tablet (oral) | Levoxyl | 32 products, 16 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Levothyroxine →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA021301 | King Pharms | May 25, 2001 | 11 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| levothyroxine sodium 100 ug tablet | Brand: Levoxyl | $0.9708 per tablet Generic of the same strength and form: $0.0495 per tablet |
| levothyroxine sodium 112 ug tablet | Brand: Levoxyl | $1.12 per tablet Generic of the same strength and form: $0.0579 per tablet |
| levothyroxine sodium 125 ug tablet | Brand: Levoxyl | $1.13 per tablet Generic of the same strength and form: $0.0575 per tablet |
| levothyroxine sodium 137 ug tablet | Brand: Levoxyl | $1.15 per tablet Generic of the same strength and form: $0.0633 per tablet |
| levothyroxine sodium 150 ug tablet | Brand: Levoxyl | $1.17 per tablet Generic of the same strength and form: $0.0566 per tablet |
| levothyroxine sodium 175 ug tablet | Brand: Levoxyl | $1.39 per tablet Generic of the same strength and form: $0.0748 per tablet |
| levothyroxine sodium 200 ug tablet | Brand: Levoxyl | $1.34 per tablet Generic of the same strength and form: $0.0849 per tablet |
| levothyroxine sodium 25 ug tablet | Brand: Levoxyl | $0.7529 per tablet Generic of the same strength and form: $0.0352 per tablet |
| levothyroxine sodium 50 ug tablet | Brand: Levoxyl | $0.8540 per tablet Generic of the same strength and form: $0.0401 per tablet |
| levothyroxine sodium 75 ug tablet | Brand: Levoxyl | $0.9449 per tablet Generic of the same strength and form: $0.0468 per tablet |
| levothyroxine sodium 88 ug tablet | Brand: Levoxyl | $0.9597 per tablet Generic of the same strength and form: $0.0476 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Levoxyl
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Levoxyl products.
- Pfizer Laboratories Div Pfizer Inc11 products
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
July 29, 2025 · Class II · Ongoing · D-0575-2025
Subpotent drug
Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851-01. — Pfizer
-
March 15, 2021 · Class II · Terminated · D-0557-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
LEVOXYL Tablets, USD, 150MCG, 100-count bottle, Rx Only, Distributed by Pfizer Inc., New York, NY 10017, MADE IN AUSTRIA, NDC: 60793-858-01 — Cardinal Health Inc.
-
December 6, 2018 · Class II · Terminated · D-0339-2019
Superpotent Drug.
Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle, Rx Only,Distributed by Pfizer Inc. New York, NY 10017, NDC 60793-855-01 — Pfizer Inc.
-
November 7, 2016 · Class II · Terminated · D-0150-2017
Superpotent
LEVOXYL(R) (levothyroxine sodium tablets, USP), 200 mcg, 100 count bottles, Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620, NDC 60793-860-01 — Pfizer Inc.
-
April 30, 2013 · Class II · Terminated · D-425-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 100 mcg, packaged in a) 100-count bottles (NDC 60793-854-01) and b) 1000-count bottles (NDC 60793-854-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc. — King Legacy, a wholly owned subsidiary of Pfizer
-
April 30, 2013 · Class II · Terminated · D-427-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 125 mcg, packaged in a) 100-count bottles (NDC 60793-856-01) and b) 1000-count bottles (NDC 60793-856-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc. — King Legacy, a wholly owned subsidiary of Pfizer
-
April 30, 2013 · Class II · Terminated · D-430-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 175 mcg, packaged in a) 100-count bottles (NDC 60793-859-01) and b) 1000-count bottles (NDC 60793-859-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc. — King Legacy, a wholly owned subsidiary of Pfizer
-
April 30, 2013 · Class II · Terminated · D-422-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 50 mcg, packaged in a) 100-count bottles (NDC 60793-851-01) and b) 1000-count bottles (NDC 60793-851-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., — King Legacy, a wholly owned subsidiary of Pfizer
-
April 30, 2013 · Class II · Terminated · D-428-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 137 mcg, packaged in a) 100-count bottles (NDC 60793-857-01) and b) 1000-count bottles (NDC 60793-857-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc. — King Legacy, a wholly owned subsidiary of Pfizer
-
April 30, 2013 · Class II · Terminated · D-426-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 112 mcg, packaged in a) 100-count bottles (NDC 60793-855-01) and b) 1000-count bottles (NDC 60793-855-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc. — King Legacy, a wholly owned subsidiary of Pfizer
-
April 30, 2013 · Class II · Terminated · D-423-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 75 mcg, packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles (NDC 60793-852-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., — King Legacy, a wholly owned subsidiary of Pfizer
-
April 30, 2013 · Class II · Terminated · D-421-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 25 mcg, packaged in a) 100-count bottles (NDC 60793-850-01) and b) 1000-count bottles (NDC 60793-850-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., — King Legacy, a wholly owned subsidiary of Pfizer
-
April 30, 2013 · Class II · Terminated · D-431-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc. — King Legacy, a wholly owned subsidiary of Pfizer
-
April 30, 2013 · Class II · Terminated · D-424-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 88 mcg, packaged in a) 100-count bottles (NDC 60793-853-01) and b) 1000-count bottles (NDC 60793-853-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., — King Legacy, a wholly owned subsidiary of Pfizer
-
April 30, 2013 · Class II · Terminated · D-429-2013
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc. — King Legacy, a wholly owned subsidiary of Pfizer
Showing the newest 15 of 26.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.